Pharmaron Beijing Co (HKSE:03759) Research & Development: HK$657 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03759 Pharmaron Beijing Co Ltd HKSE:03759
93 GF Score
Price HK$23.66
GF Value HK$20.47
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Research & Development?

Pharmaron Beijing Co HKSE:03759 -0.17% 93 Research & Development is HK$657 Mil as of Mar. 2026. GuruFocus rates HKSE:03759 with a GF Score™ of 93/100 and a GF Value™ of HK$20.47 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pharmaron Beijing Co's Research & Development for the three months ended in Mar. 2026 was HK$159 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was HK$657 Mil.

Pharmaron Beijing Co  (HKSE:03759) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pharmaron Beijing Co Research & Development Related Terms

Pharmaron Beijing Co Research & Development Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Research & Development Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 185.84 315.28 490.32 501.02 636.34

Pharmaron Beijing Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.04 140.19 154.24 203.74 158.72
HKSE:03759
93GF Score
Pharmaron Beijing Co Ltd HKSE:03759
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$657 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$657 Mil mean?
Pharmaron Beijing Co (HKSE:03759) has a Research & Development of HK$657 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Research & Development too high?
Pharmaron Beijing Co's current Research & Development is HK$657 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Research & Development compare to VRTX and REGN?
Pharmaron Beijing Co's Research & Development of HK$657 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Research & Development is HK$657 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$20.47, compared to a current price of HK$23.66 — trading 15.6% above its estimated fair value. The current Research & Development is HK$657 Mil. Pharmaron Beijing Co's overall GF Score™ is 93/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current Research & Development is HK$657 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of HK$23.66 is trading 15.6% above its estimated GF Value™ of HK$20.47. GuruFocus considers Pharmaron Beijing Co to be Modestly Overvalued.

Key valuation signals for HKSE:03759:

  • Research & Development: HK$657 Mil
  • GF Value™: HK$20.47 vs. price of HK$23.66 (15.6% above fair value)
  • GF Score™: 93/100 with 9 warning signs

No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Other Exchanges 17Q1:Germany300759:China
Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
93GF Score

Get the complete analysis for HKSE:03759

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$23.66
Price
HK$20.47
GF Value